CraniSeal Dural Sealant
Pramand, LLC · Decision date Oct 1, 2026
What did the FDA approve?
FDA approved a revised protocol for the CraniSeal Registry New Enrollment Post-Approval Study (PAS) for the CraniSeal Dural Sealant from Pramand, LLC. The supplement, identified as P220014/S013, was submitted to satisfy conditions of approval in the original P220014 approval order.
The decision is limited to the PAS protocol revision; it is not a new approval of the dural sealant device itself. The source statement does not describe what specific changes were made to the protocol, nor does it provide details about the study design, endpoints, or enrollment criteria. The device is categorized as a dural sealant under product code NQR.
FDA approval order statement
Approval of the revised protocol for the CraniSeal Registry New Enrollment Post-Approval Study (PAS). The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P220014.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Neurology
- Decision date
- Oct 1, 2026
- FDA change category
- Postapproval Study Protocol
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P220014/S013
- Regulatory pathway
- PMA supplement
- Applicant
- Pramand, LLC
- Product code
- NQR
- Decision code
- APPR
- Decision date
- Oct 1, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Sealant, dural.
- Applicant
- Pramand, LLC
- Product code
- NQR
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P220014. Subsequent supplements may change the device or its indications.
FDA decision timeline
P220014 · Original PMA
CraniSeal Dural Sealant
P220014/S013 received
Application receipt date recorded by FDA.
P220014/S013 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P220014. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P220014
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
CraniSeal Dural SealantP220014 | Pramand, LLC | PMA approval | Jul 6, 2023 | FDA |
Explore the linked device profile
Other records with product code NQR
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
SpineSeal Spine SealantP240027/S007 | Pramand, LLC | PMA supplement | Sep 11, 2026 | FDA |
SpineSeal Spine SealantP240027 | Pramand, LLC | PMA approval | Feb 14, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Pramand, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 201 Burlington Rd., Suite 210, Bedford, MA, 01730
Sources and methodology
- Original FDA record: P220014/S013
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

